Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HTZ
6. INFY
7. HONA
8. TTWO
9. QCOM
10. HELP

Go back to Gilead's (GILD) Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

Gilead Sciences (GILD) Announces Jeffrey A. Bluestone to Board

December 8, 2020 4:11 PM EST

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Jeffrey A. Bluestone, PhD, has been appointed to the companys Board of Directors.

Dr. Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology at the University of California San Francisco. He is an international leader in the field of immunotherapy and has published more than 500 papers over... More